Benzinga

Benzinga

Benzinga

lundi, septembre 07

Hemab Therapeutics Holdings Inc

COAGNASDAQ
Trade with Public
Trade with Public
$44.41
0.040.09%
À la clôture: Sep 4, 5:00 PM EST
$44.36
-0.05-0.11%
Après les heures: Sep 4, 4:53 AM EST
AperçuActualitésPrévisions de résultatsÉvénementsObjectifs de coursDonnées financièresSentimentActionnariatComparerRapport sur les stocks

Hemab Therapeutics Hldgs Analyst Price Targets

Wall Street analyst price targets and consensus rating for Hemab Therapeutics Hldgs (COAG).

Price Target Range — 2 Quarters

Analyst Consensus — 5 Analysts

5Buy
Consensus RatingBuy# Analysts5Avg. Consensus PT$51Upside to Avg. PT+15.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 12, 2026WedbushDavid NierengartenPT RaiseOutperform$55→$64
Aug 11, 2026HC Wainwright & Co.Emily BodnarPT RaiseBuy$52→$60
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Wedbush Maintains Outperform on Hemab Therapeutics Hldgs, Raises Price Target to $64

Wedbush analyst David Nierengarten maintains Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Outperform and raises the price target from $55 to $64.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Hemab Therapeutics Hldgs, Raises Price Target to $60

HC Wainwright & Co. analyst Emily Bodnar maintains Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy and raises the price target from $52 to $60.
Benzinga Newsdesk

PRO
Jefferies Maintains Buy on Hemab Therapeutics Hldgs, Raises Price Target to $47

Jefferies analyst Maury Raycroft maintains Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy and raises the price target from $39 to $47.
Benzinga Newsdesk

PRO
CORRECTION: Wedbush Maintains Outperform on Hemab Therapeutics Hldgs, Raises Price Target To $55

Wedbush analyst David Nierengarten maintains Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Outperform and raises the price target from $42 to $55.
Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Hemab Therapeutics Hldgs, Maintains $55 Price Target

Wedbush analyst David Nierengarten reiterates Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Outperform and maintains $55 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Hemab Therapeutics Hldgs, Raises Price Target to $52

HC Wainwright & Co. analyst Emily Bodnar maintains Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy and raises the price target from $40 to $52.
Benzinga Newsdesk

Données et API: API Benzinga · API d'actualités boursières · API de notations d'analystes · API de logo d'entreprise

Données de marché fournies par API Benzinga

Benzinga

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

© 2026 Benzinga | All Rights Reserved